Assessing Dentsply Sirona (XRAY) Valuation After Steep Share Price And Earnings Setbacks

DENTSPLY SIRONA (XRAY) stock has drawn attention after a period of weak share performance, with the price around $9.84 and total returns down over the past year and over the past 3 months.

See our latest analysis for DENTSPLY SIRONA.

The recent 1-day share price return of 1.03% sits against a 30-day share price return that is down 23.06% and a 1-year total shareholder return that is down 35.47%, suggesting momentum has been fading rather than building.

If this kind of volatility has you looking across healthcare, it could be worth scanning for other opportunities in 30 healthcare AI stocks

With revenue growth, a recent loss, and valuation markers like a value score of 6 and an intrinsic discount indicator, is DENTSPLY SIRONA a mispriced healthcare stock, or is the market already accounting for its future growth potential?

Most Popular Narrative: 78.4% Undervalued

According to the most followed narrative, DENTSPLY SIRONA's fair value is set at $45.50 against a last close of $9.84, painting a wide valuation gap that hinges on how durable its dental demand and earnings potential prove to be.

Dentsply Sirona (NASDAQ: XRAY) operates in a corner of healthcare that rarely attracts hype but consistently demands precision. As one of the world’s largest dental equipment and consumables providers, the company sits upstream from patient demand, selling to dental practices rather than consumers. That position shapes everything about its business, from revenue stability to growth expectations.

Read the complete narrative.

Curious how that fair value is built? The narrative leans on steady procedure volumes, resilient consumables demand, and profit margins that hinge on disciplined execution rather than rapid expansion.

Result: Fair Value of $45.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this durability story faces real pressure if dental equipment cycles stay soft or if losses such as the recent US$628 million result persist for longer than expected.

Find out about the key risks to this DENTSPLY SIRONA narrative.

Next Steps

With sentiment clearly on edge after the recent share price weakness, it makes sense to move fast, check the underlying data yourself, and weigh up what still looks attractive in the story, starting with the 4 key rewards.

Looking for more investment ideas?

If DENTSPLY SIRONA has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that match clear, data driven criteria.

• Target higher potential returns by reviewing carefully selected value opportunities through the 51 high quality undervalued stocks.
• Strengthen your income stream by examining companies highlighted as potential yield anchors in the 10 dividend fortresses.
• Reduce portfolio stress by focusing on stability first with the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com